Meng H. Tan - Concepedia

Author

Meng H. Tan

Eli Lilly (United States)ORCID

Also Known As

Brigid Gregg, Jane Pinaire, M H Tan, M Mozhy Mahizhnan, M. H. TAN, M. H. Tan, M. Tan, M.H. Tan, MENG TAN, Meirong Tan

168

Publications

13.2K

Citations

H-Index

123

Concepts

All Affiliations

Eli Lilly (United States)Dalhousie University University of Michigan Harvard University Takeda (United States)

About

Meng H. Tan is an author at Eli Lilly (United States) specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	42	7.6K
2	Health Sciences	13	17	908
3	Public Health	10	10	4.6K
4	Social Sciences	2	2	54
5	Nursing	1	1	129

Meng H. Tan

Publications

10.8K

Citations

H-Index

Page 1

	Year	Citations
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial John Dormandy, B Charbonnel, D.J.A. Eckland, The Lancet Diabetes ManagementCardiovascular DiseaseHealth PolicyDiabetesSecondary Prevention	2005	4.1K
Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study Philippe Ryvlin, Lina Nashef, Samden D. Lhatoo, The Lancet Neurology Retrospective StudyCardiopulmonary ResuscitationMedicinePatient SafetyConcussion	2013	1.1K
A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Ronald Goldberg, David M. Kendall, Mark A. Deeg, Diabetes Care	2005	795
Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease Erland Erdmann, B Charbonnel, Robert A. Wilcox, Diabetes Care	2007	280
Increased Lipoprotein-Remnant Formation in Chronic Renal Failure Paul J. Nestel, Noel Fidge, Meng H. Tan New England Journal of Medicine Long-term DialysisRenal PathologyPathologyRemnant Particle AccumulationHyperlipidemia	1982	240
Pioglitazone Reduces Atherogenic Index of Plasma in Patients with Type 2 Diabetes Meng H. Tan, Don Johns, N. Bradly Glazer Clinical Chemistry	2004	207
Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States Stephanie N. DuBose, Julia M. Hermann, William V. Tamborlane, The Journal of Pediatrics ObesityMetabolic SyndromeType 1Childhood ObesityHealth Policy	2015	177
Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia Mark A. Deeg, John B. Buse, Ronald Goldberg, Diabetes Care	2007	177
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes B Charbonnel, Guntram Schernthaner, P. Brunetti, Diabetologia Diabetes ManagementLong-term EfficacyDiabetesPharmacologyType 2	2005	170
Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes Imre Pávó, György Jermendy, Tamás Várkonyi, The Journal of Clinical Endocrinology & Metabolism Metabolic SyndromeInsulin SensitivityDiabetes ManagementInsulin ManagementDiabetes	2003	164

Page 1